Literature DB >> 8764187

Effects of glucagon-like peptide-I on glucose turnover in rats.

G Van Dijk1, S Lindskog, J J Holst, A B Steffens, B Ahrén.   

Abstract

The influences of glucagon-like peptide-I-(7-36) amide (GLP-I; 15 mumol. kg-1.min-1) on glucose turnover were studied in freely moving Wistar rats. In fed rats, GLP-1 reduced plasma glucose (from 7.3 +/- 0.2 to 5.6 +/- 0.3 mmol/l; P = 0.017), increased plasma insulin (from 20 +/- 3 to 89 +/- 11 mU/l; P = 0.002), and reduced plasma glucagon (from 44 +/- 1 to 35 +/- 2 pg/ml; P = 0.009) and glucose appearance rate (Ra; from 3.9 +/- 0.2 to 1.7 +/- 0.7 micromol.min-1. 100 g-1 after 30 min; P = 0.049) without affecting glucose disappearance rate (Rd). The glucose clearance rate (MCR) was increased (P = 0.048). In 48-h-fasted rats, GLP-I reduced plasma glucose (from 5.0 +/- 0.2 to 4.4 +/- 0.3 mmol/l; P = 0.035) and increased plasma insulin (from 4 +/- 1 to 25 +/- 10 mU/l; P = 0.042) and plasma glucagon (from 43 +/- 3 to 61 +/- 7 pg/ml; P = 0.046). Ra and Rd were not significantly affected, although Ra was lower than Rd after 15-30 min (P = 0.005) and MCR was increased (P = 0.049). Thus GLP-I reduces Ra in fed rats and increases MCR in fed and fasted rats. The reduced Ra seems mediated by an increased insulin-to-glucagon ratio; the increased glucose clearance seems dependent on insulin and a peripheral effect of GLP-I.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8764187     DOI: 10.1152/ajpendo.1996.270.6.E1015

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  7 in total

Review 1.  Gut hormones ghrelin, PYY, and GLP-1 in the regulation of energy balance [corrected] and metabolism.

Authors:  Diego Perez-Tilve; Ruben Nogueiras; Federico Mallo; Stephen C Benoit; Matthias Tschoep
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

Review 2.  Alpha cell function in health and disease: influence of glucagon-like peptide-1.

Authors:  B E Dunning; J E Foley; B Ahrén
Journal:  Diabetologia       Date:  2005-08-13       Impact factor: 10.122

3.  Pleiotropic effects of incretins.

Authors:  Vishal Gupta
Journal:  Indian J Endocrinol Metab       Date:  2012-03

4.  Incretin-based therapies: new treatments for type 2 diabetes in the new millennium.

Authors:  Joan Khoo; Christopher K Rayner; Karen L Jones; Michael Horowitz
Journal:  Ther Clin Risk Manag       Date:  2009-08-20       Impact factor: 2.423

Review 5.  The Insulin Response to Oral Glucose in GIP and GLP-1 Receptor Knockout Mice: Review of the Literature and Stepwise Glucose Dose Response Studies in Female Mice.

Authors:  Bo Ahrén; Yuichiro Yamada; Yutaka Seino
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-27       Impact factor: 5.555

6.  GLP-1 receptor antagonist exendin-(9-39) elevates fasting blood glucose levels in congenital hyperinsulinism owing to inactivating mutations in the ATP-sensitive K+ channel.

Authors:  Andrew C Calabria; Changhong Li; Paul R Gallagher; Charles A Stanley; Diva D De León
Journal:  Diabetes       Date:  2012-08-01       Impact factor: 9.461

7.  Impact of Incretin Hormone Receptors on Insulin-Independent Glucose Disposal in Model Experiments in Mice.

Authors:  Tina Ovlund; Giovanni Pacini; Bo Ahrén
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-08       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.